Pyoderma Gangrenosum: Retrospective Evaluation of Clinical Features and Treatment Responses in 23 Cases

Authors : Zeynep Büşra Balik, Gülşen Akoğlu

Pages : 307-312

View : 30 | Download : 27

Publication Date : 2023-09-30

Article Type : Research

Abstract :Pyoderma gangrenosum (PG) is a rare inflammatory disease in the spectrum of neutrophilic diseases characterized by rapidly progressive, painful and large ulcers. In this study, we aimed to investigate the relationship between the clinical characteristics and treatment responses of patients diagnosed with PG, treated and followed up in our clinic. Between 2018 and 2023, 23 patients diagnosed with PG in our clinic were included in the study. Medical file records were retrospectively analyzed and various demographic and clinical characteristics, comorbid systemic diseases, treatment protocols and treatment responses of the patients were recorded. Twelve (52.2%) of the patients were female and 11 (47.8%) were male, with a mean age of 42.4±12.9 years. The median disease duration was 52 months (range: 10-540 months). Systemic diseases accompanying PG were present in 14 patients (60.9%). Systemic steroids were the most common treatment (43.5%). Other treatment approaches included adalimumab, infliximab, cyclosporine, oral doxycycline, topical tacrolimus, topical corticosteroids and intralesional steroids. Remission was achieved in 14 patients (60.9%), relapse was observed in 5 patients (21.74%), and no remission/relapse information was available for 4 patients (17.4%) who lost follow-up. The median duration of remission was 23 months (range: 3-96 months). Although systemic steroids are most commonly used in the treatment of pyoderma gangrenosum, it should be kept in mind that there are various treatment options ranging from systemic and topical anti-inflammatory therapies to biologic agents according to close follow-up of the patients and additional systemic diseases.
Keywords : pyoderma gangrenosum, concomitant systemic diseases, treatment